Category: Corporate Collaborations

Corporate Collaborations

2018 Trajectory Next accelerator program companies selected, program on…

2018 Trajectory Next accelerator program companies selected, program on track

The 2018 cohort of Trajectory Next participates in a June 6, 2018 session of the 12-week program for digital health, bio-health and life sciences startups.
Betamore, Johns Hopkins Technology Ventures and the University of Maryland, Baltimore’s UM Ventures have launched 2018’s Trajectory Next, a post-accelerator program designed to support digital health, bio-health and life sciences ventures.

The 12-week program is funded through the TEDCO Incubation Challenge and will be housed among the three collaborating institutions. It will offer support, guidance and access to the combined networks of Betamore, JHTV and UM Ventures.

Companies with backgrounds in digital health, bio-health innovation or life sciences located in Maryland or willing to relocate to Maryland have been selected for the 2018 session. The program began May 23 and will end Sept. 12.

The companies are:

CardioCube is a voice-based AI software that is an everyday assistant to help manage heart disease. Talking to CardioCube is like talking to a best friend and cardiologist at the same time while the patient’s doctor gets medical insights for better and faster decisions.

Bayesian Health provides machine learning driven end-to-end protocols that give care teams actionable information in real-time to enable rapid and sustainable performance improvement.

Revolve Biotechnologies, Inc. has developed a protein and nucleic acid evolution platform for discovering lead candidates from libraries of billions of variants. Revolve is applying the platform toward creating products in three focus areas, including high-affinity antibodies, oncolytic ribozymes and infrared fluorescent proteins. The company also offers a custom library generation and antibody discovery service for clients in the biotech/biopharma fields.

NextStep Robotics Inc. is developing the first effective treatment option for foot drop to help stroke survivors and others regain mobility using clinically proven rehabilitation robotics training. Their first product is AMBLE, a novel, portable ankle robot for foot drop.

LyfLynks, Inc. is developing a comprehensive solution for family caregiving that will disrupt the $70 billion eldercare market. By combining Mobile, Call Center and IoT technologies, the platform simplifies the lives of caregivers — enabling them to spend less time coordinating the day-to-day needs of elders and spend more time enriching the lives of their loved ones.

B.Well connects all aspects of a consumer’s health care in a single place so that they can seamlessly interact and engage with their lifelong health and wellness. Their platform allows you to safely and securely store, manage, and share your medical records and family health history all in one place, as well as view financial information about your benefit plan, co-pays, deductibles and the cost of prescriptions at nearby pharmacies.

Sonavex is committed to improving outcomes for surgical patients by using cutting-edge imaging technology to provide clinicians with visualization of critical data — directly at the point of care. The company has received 510(k)s to the FDA for its EchoMark Device and plans to launch commercially by the end of the year.

ClearMask is developing the first full-face transparent surgical mask to humanize health care and improve communication. ClearMask helps hospitals reduce patient anxiety and costly medical errors from miscommunication while improving patient satisfaction and cultural competency.

The 12-week program offers participants customized services and training around the building of sales channels, facilitating pilot programs, restructuring product management, legal support, user research, market development and recruiting.

Companies will be working with McDonell Consulting Group (MCG)/Sandler Training throughout the 12-week program to receive personalized, responsive training tailored to their sales, management, and leadership needs.

“We look forward to leveraging the strengths of each partner organization to provide the highest quality resources to accelerate the growth of these companies,” says Greg Cangialosi, co-founder and Chairman at Betamore. “The combined networks of Betamore, JHTV, and UM Ventures is what makes Trajectory Next unique.”

Established in 2012, Betamore is an award-winning co-working space, incubator and campus for technology and entrepreneurship. Betamore has been home to 146+ companies that have collectively raised more than $103M in venture capital and in 2017 contributed $28.5M to Baltimore City’s economy.

“We saw an unmet need in the entrepreneurial space for a post-accelerator training program that develops the unique skills needed for early sales and tapped our networks across the state to help startups shorten the health care sales cycle,” says Megan Wahler, FastForward Program Manager at Johns Hopkins Technology Ventures. “Beyond the teams participating we have had a great response from industry and institutions looking to get involved.”

Johns Hopkins Technology Ventures (JHTV) is The Johns Hopkins University’s intellectual property administration center, serving Johns Hopkins researchers and inventors as a licensing, patent and technology commercialization office and acting as an active liaison to parties interested in leveraging university research or materials for academic or corporate endeavors.

JHTV helps develop new discoveries and inventions into products and services that benefit society and transform the world. In 2016, JHTV secured more than $58 million in licensing revenue, possessed more than 2,454 active issued patents and created 22 new startup companies.

Subscribe to the Johns Hopkins Tech Ventures newsletter!

Corporate Collaborations

Johns Hopkins-IP Group Collaboration Funds Cancer Therapeutic Startup, Paves…

Johns Hopkins-IP Group Collaboration Funds Cancer Therapeutic Startup, Paves Way for Further IP Commercialization

Barbara Slusher, Ph.D., M.A.S., professor of neurology, psychiatry, neuroscience, medicine and oncology

The Johns Hopkins University announces that IP Group has funded the creation of Lorem Therapeutics as part of an ongoing collaboration between the university and the intellectual property commercialization company to explore, identify and commercialize technologies. Lorem will be focused on developing early-stage therapeutics, bridging the gap from drug discovery to investigative new drug (IND) status, specifically novel small molecule prodrugs for cancer indications.

“The relationship Johns Hopkins has forged with IP Group aims to facilitate one of our institution’s long-standing missions—to bring the benefits of discovery to the world,” says Christy Wyskiel, senior adviser to the president for enterprise development and the head of Johns Hopkins Technology Ventures, the university’s intellectual property administration center. “The support provided to early stage technologies through this model of venture creation has the potential to accelerate the transformation of promising research into impactful products and services.”

Lorem is led by Barbara Slusher, Ph.D., M.A.S., professor of neurology, psychiatry, neuroscience, medicine and oncology at the Johns Hopkins University School of Medicine, who has an extensive track record of bringing lead compounds from drug discovery through clinical development. Slusher directs Johns Hopkins Drug Discovery, the largest integrated drug discovery program at the university, with a veteran team of medicinal chemists, assay developers, pharmacologists, toxicologists and pharmacokinetic and drug metabolism experts. The team is engaged in identifying novel drug targets arising from the university’s research efforts and translating them into new drug therapies for clinical development.

“We are excited to announce the first investment from our collaboration with Johns Hopkins University,” says Michael Burychka, chief executive officer, IP Group North America. “IP Group is committed to supporting scientific discovery and is thrilled to work with Dr. Slusher. We look forward to building upon our relationship with Johns Hopkins and continuing to invest in novel science being developed at the university.”

Accompanying the initial funding, Lorem Therapeutics will receive support from FastForward, a coordinated suite of resources managed by Johns Hopkins Technology Ventures that provides more than 100 startups with access to affordable space, services and funding opportunities.

“I am delighted to have the support of IP Group, Johns Hopkins Technology Ventures and FastForward as we launch this exciting venture,” Slusher says. “IP Group’s commercial expertise and initial funding as well as FastForward’s ongoing support will play a critical role in helping us accelerate and enhance our drug discovery efforts around critical cancer indications.”


Subscribe to the Johns Hopkins Tech Ventures newsletter!

WP-Backgrounds Lite by InoPlugs Web Design and Juwelier Schönmann 1010 Wien